Answers are grounded in this paper and cite their sources.
Background and aim PF-07242813 (anti-CD1a) was designed to inhibit T-cell proinflammatory signaling. This analysis evaluated the safety and pharmacokinetics of single ascending doses (SAD) and multiple ascending doses (MAD) of PF-07242813 in healthy participants and pharmacodynamics of a single dose in patients with atopic dermatitis. Methods In Part 1, healthy participants (18–55 years) received PF-07242813 intravenously (IV; SAD), subcutaneously (SC; MAD) or IV (MAD), or placebo. In Part 2, patients with moderate-to-severe atopic dermatitis (18–65 years) were randomized (2:1) to receive PF-07242813 1000 mg IV or placebo. Endpoints included safety and pharmacokinetic outcomes in healthy participants and efficacy endpoints in patients with atopic dermatitis. Results Of the 122 participants (SAD: n=57; MAD: n=40; atopic dermatitis: n=25), 41 reported treatment-emergent adverse events (mostly mild); headache (4.9%) and alanine transaminase increased (4.9%) were most common. Peak serum PF-07242813 concentrations were 0.6–2 hours (IV, SAD) and 73–169 hours (SC, MAD). Overall, PF-07242813 did not demonstrate clinical benefit in patients with atopic dermatitis. Conclusions CD1a blockade is not sufficient to produce a clinical effect in patients with atopic dermatitis. PF-07242813 was well-tolerated and may be useful for CD1a pathway analyses. ClinicalTrials.gov Identifier NCT04668066
No takes yet. Share an insight, caveat, or question.
Danto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: